U.S. Markets open in 8 hrs 35 mins
  • S&P Futures

    3,650.00
    -4.25 (-0.12%)
     
  • Dow Futures

    29,212.00
    -73.00 (-0.25%)
     
  • Nasdaq Futures

    11,217.25
    -11.00 (-0.10%)
     
  • Russell 2000 Futures

    1,679.30
    -2.80 (-0.17%)
     
  • Crude Oil

    80.87
    -0.36 (-0.44%)
     
  • Gold

    1,671.00
    +2.40 (+0.14%)
     
  • Silver

    18.83
    +0.12 (+0.63%)
     
  • EUR/USD

    0.9809
    -0.0011 (-0.1079%)
     
  • 10-Yr Bond

    3.7470
    0.0000 (0.00%)
     
  • Vix

    31.84
    +1.66 (+5.50%)
     
  • GBP/USD

    1.1108
    -0.0015 (-0.1344%)
     
  • USD/JPY

    144.6210
    +0.1780 (+0.1232%)
     
  • BTC-USD

    19,442.93
    -118.31 (-0.60%)
     
  • CMC Crypto 200

    444.18
    -1.81 (-0.40%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    25,813.94
    -608.11 (-2.30%)
     

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer

·1 min read
  • The European Commission (EC) has approved Ipsen SA's (OTC: IPSEY) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting.

  • The approval covers adult patients with locally advanced or metastatic DTC, refractory or not eligible for radioactive iodine, who have progressed during or after systemic therapy.

  • This EC approval follows the FDA approval announced by Exelixis Inc (NASDAQ: EXEL) in September 2021 of Cabometyx for adult and pediatric patients with locally advanced or metastatic DTC.

  • The approval was based on results from the COSMIC-311 Phase 3 trial, which at a planned interim analysis, demonstrated a significant reduction in the risk of disease progression or death by 78% versus placebo.

  • The objective response rate also favored Cabometyx with 15% vs. 0% for placebo (p=0.028) but did not meet the criteria for statistical significance.

  • At a median follow-up of 10.1 months, the final results demonstrated Cabometyx's median PFS of 11.0 months versus 1.9 months with placebo and a maintained reduction in disease progression or death risk of 78% versus placebo.

  • Price Action: EXEL shares closed 1.43% higher at $22.66 on Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.